**Oncology** Partnering Convention

Opening 9.45 - 10.00

Round table #1: Spotlights on the future of oncology

# 10.00 / 10.50 am

**May 16** 

01

02

04

05

06

024

Moderation; Muriel Dahan (Unicancer, R&D Director)

- Introduction & overview on the oncology landscape: J.Yves Blay (Unicancer President)
- The oncogenomics revolution: Antoine Italiano (Head Early Phase Trials & Sarcoma Unit, Institut Bergonié)
- Al for the diagnosis of CUP: Julien Vibert (Gustave Roussy, MD Assistant clinical manager)
- Therapeutic vaccines: François Ghiringhelli (Centre Georges-François Leclerc, Medical Oncology Prof)
- New-generation ADCs: Charles Dumontet (CRCL, Deputy Director & Chair of Hosp Civils de Lyon council)

Round table #2: Convergence of interests: What do startups expect? What do pharma companies expect? What are the keys to successful deals and collaboration?

### 10.50 / 11.50 am

Moderation: J.Yves Bonnefoy (Salto Therapeutics / Syndivia)

- Sasha Koniev (Syndivia, CEO)
- Eric Halioua (PDC\*line Pharma, CEO)
- Karine Rossignol (Smart Immune, CEO)
- Karine Chorro (Phost'In, CEO)
- Frederic Caroff (Hephaïstos, CEO)
- Khatereh Ahmadi (MSD, Exec Director Oncology Search & Evaluation)
- Sasha Huhalov (TAKEDA, Head Oncology Search & Evaluation)

B2B meetings(30 mn)

Meet your future partners, providers, employees...

1.30 / 6 pm

O3 QUICK PITCH session (10 pitchs x 5mn innovative projects) - public and MATWIN Board vote 11.50 / 12.50

## Lunch 12.50 / 2.00 pm

04

Thematic workshops (30 mn)

# 2.00 / 5.30 pm

Partners workshops (30 mn each)

- FORTREA : Dr Moez Benali, MD- PhD Senior Medical Director
- MEDIAN Technologies : Guillaume Loreille, Business Development Director & BioMaps / PASREL Imagerie : Charles Truillet, Head of the Oncolmaging Laboratory
- INOVOTION : Jean Viallet, CEO
- Science4Tech : Jordi Guitart, CEO & Joris Brenninkmeijer, Enterprise Sales Executive
- Voisin Consulting Life Sciences : Soraya Sin-Monnot, Program Manager Neighborhood

# Champagne Connection:

Celebrate MATWIN's 15 years & network with MATWIN Alumni with a glass of champagne!

# 6.00 / 7.00 pm

Cocktail birthday party: let's meet, match and dance (IBAIA cafe) 8.00 / 11.00 pm





May 17 ..\_\_\_



2024

**MEET my Company - Exact Sciences,** Rick Baehner, Cheif Medical Officer, Precision Oncology **P**resentation of the Exact Sciences R&D strategy

## 9.00 / 9.30 am

MEET my Company - Pierre Fabre, Anna Kruckzynski, External Science & Innovation Director
Presentation of the Pierre Fabre R&D strategy
9.30 / 10.00 am



**MEET My Alumni**: meet  $\pm$  10 former MATWIN entrepreneurs for a poster session offering a snapshot on their company

## 10.00 / 11.00 am



Round table #3 : Accelerating the transformation of health innovation - let's compare our ecosystems and organizations! Sharing experience of start-ups from different ecosystems **11.00 / 12.00 am** 

Moderation: Lucia Robert (MATWIN, CEO) - Benjamin Garel (Paris Saclay Cancer Cluster, CEO)

- The Boston ecosystem: Dominique Verhelle (NextRNA Therapeutics, CEO)
- Belgium: Eric Halioua (PDC\*line Pharma, CEO)
- Quebec: Etienne Laurent (MISO Chip, CEO)
- Netherlands: to be announced

Awards ceremony for QUICK PITCH, OUI & MATWIN

## 12.00 / 12.15 am

Lunch 12.15 / 2.00 pm



04

B2B meetings(30 mn)

1.30 / 4.30 pm

Meet your future partners, providers, employees...

# An event organized by



B2B meetings(30 mn)

9.00 am / 4.30 pm







# WORKSHOPS WORKSHOP 1: 14h00



Moez BEN ALI MD, PhD Senior Medical Director

# Fortrea

### How precision medicine impacts clinical development nowadays?

Over the last decade, many new mutations that cause cancer and so act as targets for therapy, have been discovered. The discovery of cancer-related genes was really empowered by the next generation sequencing technique. This technology can screen and survey hundreds of mutations simultaneously, bringing a positive new approach to cancer care for the next few years.

This new area of precision medicine requires new tools and, also innovative designs for clinical trials. Fortrea, an agile global partner offers a wide range of solutions to support precision medicine from clinical trial design to the execution of a clinical study. We are going to focus on the clinical development discussing innovative design, modeling simulation, RWD and RWE for pre-screening to accelerate your pipeline and support our common main target :The Patients.

## WORKSHOP 3: 15h30





Guillaume Loreille Median Technologies

**Charles Truillet** Business Development Director Head of the Oncolmaging Laboratory - BioMaps / PASREL-Imagerie





Median Technologies and PASREL-Imagerie join forces to deliver smart imaging biomarkers supporting the development of new oncology drugs in precision medicine

Median Technologies, a CRO specialized in imaging, and PASREL-Imagerie, a CEA consortium of preclinical and clinical medical imaging platforms, are combining their strengths and know-how to offer a range of advanced biomarkers for early-phase clinical trials in oncology.

The new capabilities resulting from this cooperation create an exceptional and unique differentiator for Median's iCRO. Similarly, this alliance reinforces PASREL-Imagerie's mission to de-risk medical innovations for the benefit of patients. The synergy brought by this new union will be introduced during the workshop.

# WORKSHOP 2: 14h45



CEO in<sub>2</sub>votion WHICH MOLECULE WILL STAND OUT

lean Viallet

### The chicken embryo model provides great added value to your oncology and immuno-oncology preclinical evaluations.

- Tremendous benefits: faster, reliable, sensitive, affordable, and predictive
- A complete physiological model to predict the effects of your treatments alone or in synergy, within the standard of care (chemotherapies, radiotherapy and immunotherapies)
- A versatile in vivo model to evaluate: tumour proliferation, metastasic invasion, angiogenesis, and immune cell interactions as well as target validation, imaging, toxicity, mechanisms of action and tumour patient avatars



Jordi Guitart CEO

Joris Brenninkmeijer **Enterprise Sales Executive** 

### From data chaos to cure: leveraging AI in the oncology practice

Join our workshop and discover how AI solutions can transform the oncology practice!

- Streamline your clinical trial search: Leverage smart algorithms to instantly match patients' diagnoses with relevant trials in your region, saving you valuable time and effort.
- Boost matching accuracy: Unlock a deeper undestanding of your patient populations through AI-powered EHR data structuring to further optimize clinical trial matching for better treatment options.

Don't miss this opportunity to learn how AI can revolutionize your approach to oncology clinical trials



#### Neighborhood, an accelerator program for health tech entrepreneurs from Voisin Consulting Life Sciences

As an accelerator of Voisin Consulting Life Sciences, Neighborhood (NGBH) supports emerging health tech start-ups, providing strategic mentoring and office space to help them grow. Through various programs dedicated to drug or medical device development, financially tailored to these smallsized companies, NGBH offers the unique opportunity to access the pool of expertise within VCLS. The consultants right next door understand the science of the start-ups and help them to derisk their development plan and to identify the most strategic regulatory path. NGBH also acts in partnership with academia (TTOs and Institutes), government agencies, associations and other innovation-focused stakeholders (science and technology parks, incubators).